Overview
Evaxion A/S (NASDAQ:EVAX) disclosed preclinical results for its cytomegalovirus (CMV) vaccine candidate EVX‑V1 at the International Herpesvirus Workshop 2026 held in Montreal, Canada, according to a Reuters press release dated 12‑07‑2026.
Preclinical Findings
The data demonstrated that AI‑discovered T‑cell epitopes enhanced control of acute CMV infection, latency and reactivation in CMV‑infected mouse models. In parallel, AI‑optimized B‑cell antigens, derived from the company’s AI‑Immunology platform, achieved viral neutralisation in the same preclinical setting. EVX‑V1 is a multi‑component vaccine that combines these AI‑identified T‑cell epitopes with AI‑optimized versions of established CMV antigens.
Market Context
CMV infects roughly 60‑70% of adults in developed economies and nearly 100% in developing economies. Approximately 1 in 200 newborns contracts congenital CMV, with about 20% of those infants experiencing disabilities or long‑term health issues. No CMV vaccine has received regulatory approval to date. The global CMV treatment market was valued at $474.6 million in 2023 and is expected to expand at a 6.6% compound annual growth rate (CAGR) from 2024 to 2032.
Company Financials and Outlook
Evaxion is a clinical‑stage biotechnology firm focused on AI‑driven vaccine development for cancer and infectious diseases. The company’s market capitalization stands at $26.44 million. Its shares have declined 33.5% year‑to‑date. InvestingPro analysis notes that Evaxion holds more cash than debt, though cash burn is rapid, typical for clinical‑stage biotech firms. Analyst price targets range from $9 to $16, indicating perceived upside from the current share price of $3.17.
Additional Pipeline Updates
The firm also announced preclinical results for EVX‑04, a therapeutic vaccine targeting acute myeloid leukemia (AML). EVX‑04 demonstrated expression and secretion in human cells, enabling immune recognition and activation. These findings were shared via a press release and are slated for presentation at the European Hematology Association Congress in Stockholm, Sweden. Evaxion plans to submit a clinical trial application for EVX‑04 in the latter half of 2026.
Other Company News
In unrelated biotech news, eGenesis announced leadership changes: Glenn S. Vraniak was appointed Chief Financial Officer and Jennifer Bergheiser was promoted to Chief Commercial Officer, supporting the company’s ongoing clinical programs for kidney failure (EGEN‑2784) and acute‑on‑chronic liver failure.